A retrospective cohort study of 5,796 cancer patients treated with immune checkpoint inhibitors found substantial underutilization of guideline-directed statin therapy among those with formal indications. Among 2,058 patients meeting guideline-defined statin indications at checkpoint inhibitor initiation, 46% were not receiving statins. Importantly for cardio-oncology practice, the analysis reported statin use was not associated with higher immune-checkpoint inhibitor toxicities such as myositis or hepatitis, and showed no statistically significant reduction in acute coronary syndrome or overall mortality over therapy. The work spotlights a gap between cardiometabolic guideline intent and real-world prescribing patterns.
Get the Daily Brief